Posted on 2/2/14

fda2WASHINGTON, D.C. (5/15/13) - The U.S. Food and Drug Administration today approved Xofigo (radium Ra 223 dichloride) to treat men with symptomatic late-stage (metastatic) castration-resistant prostate cancer that has spread to bones but not to other organs. It is intended for men whose cancer has spread after receiving medical or surgical therapy to lower testosterone.

Prostate cancer forms in a gland in the male reproductive system found below the bladder and in front of the rectum. The male sex hormone testosterone stimulates the prostate tumors to grow. According to the National Cancer Institute, an estimated 238,590 men will be diagnosed with prostate cancer and 29,720 will die from the disease in 2013.

Xofigo is being approved more than three months ahead of the product’s prescription drug user fee goal date of Aug. 14, 2013, the date the agency was scheduled to complete review of the drug application. The FDA reviewed Xofigo under the agency’s priority review program, which provides for an expedited review of drugs that appear to provide safe and effective therapy when no satisfactory alternative therapy exists, or offer significant improvement compared to marketed products.

“Xofigo binds with minerals in the bone to deliver radiation directly to bone tumors, limiting the damage to the surrounding normal tissues,” said Richard Pazdur, M.D., director of the Office of Hematology and Oncology Products in the FDA’s Center for Drug Evaluation and Research. “Xofigo is the second prostate cancer drug approved by the FDA in the past year that demonstrates an ability to extend the survival of men with metastatic prostate cancer.”

In August 2012, the FDA approved Xtandi to treat men with metastatic castration-resistant prostate cancer that has spread or recurred, even with medical or surgical therapy to minimize testosterone. Xtandi is approved for patients who have previously been treated the chemotherapy drug docetaxel.

Xofigo’s safety and effectiveness were evaluated in a single clinical trial of 809 men with symptomatic castration-resistant prostate cancer that spread to bones but not to other organs. Patients were randomly assigned to receive Xofigo or a placebo plus best standard of care.

The study was designed to measure overall survival. Results from a pre-planned interim analysis showed men receiving Xofigo lived a median of 14 months compared to a median of 11.2 months for men receiving placebo. An exploratory updated analysis conducted later in the trial confirmed Xofigo’s ability to extend overall survival.

The most common side effects reported during clinical trials in men receiving Xofigo were nausea, diarrhea, vomiting and swelling of the leg, ankle or foot. The most common abnormalities detected during blood testing included low levels of red blood cells (anemia), lymphocytes (lymphocytopenia), white blood cells (leukopenia), platelets (thrombocytopenia) and infection-fighting white blood cells (neutropenia).

Xofigo is marketed by Wayne, N.J.-based Bayer Pharmaceuticals. Xtandi is co-marketed by Astellas Pharma U.S., Inc. of Northbrook, Ill., and Medivation, Inc. of San Francisco, Calif.
SurfKY News
Information provided by the United States Food and Drug Administration your social media marketing partner

LIKE SurfKY on Facebook - Click here to LIKE us now.

© Copyright 2015 SurfKY News Group, Inc. All rights reserved. This material may not be published, broadcast, or rewritten without permission. SurfKY News encourages you to share this story on social media.

Most Read This Week

November 24, 2015 9702

Distillery to Operate in Old Graham School…

by SurfKY News
November 20, 2015 9665

Dispatchers Overhear Drug Activity during…

by SurfKY News
November 21, 2015 8629

Injuries Result from Beulah Road Accident

by Doreen Dennis, SurfKY News
November 23, 2015 7424

Relative Charged with Murder, Arson in Deaths of…

by SurfKY News
November 24, 2015 4362

Ohio County Most Wanted - Top 10 - November 24

by SurfKY News

Most Read This Month

November 17, 2015 15246

Ohio County Most Wanted - Top 10 - November 17

by SurfKY News
November 18, 2015 14333

Runaway Teen Returns on His Own

by SurfKY News

Stories Trending Now

November 25, 2015 1949

Man Hospitalized after Early Morning Car Accident

by SurfKY News
November 25, 2015 1820

Hopkins County Crime Stoppers Top Most Wanted -…

by SurfKY News
November 25, 2015 1143

Students Serve to Learn Life Lesson

by Tammy Holloway, SurfKY News
November 26, 2015 1104

Muhlenberg Sheriff's Office Makes Cocaine Bust

by SurfKY News
November 25, 2015 1039

Madisonville Police Reports Released

by SurfKY News
November 25, 2015 923

Hopkins County Sheriff's Reports Released

by SurfKY News
November 26, 2015 905

Hopkins County Health Department Food Scores…

by SurfKY News
November 25, 2015 868

Two Vehicle Collision Sends Four to Area Hospitals

by SurfKY News
November 25, 2015 859

A.G. Conway Announces $256 Million Settlement…

by SurfKY News
November 25, 2015 735

Thanksgiving is Peak Day for Cooking Fires

by SurfKY News